MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida. Show more
1200 Brickell Avenue, Miami, FL, 33131, United States
Market Cap
39.92M
52 Wk Range
$0.90 - $2.45
Previous Close
$0.95
Open
$0.96
Volume
42,935
Day Range
$0.95 - $0.99
Enterprise Value
30.51M
Cash
9.407M
Avg Qtr Burn
-1.201M
Insider Ownership
16.71%
Institutional Own.
5.03%
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Ketamir-2 Details Neuropathic pain | Phase 1 Update | |
SKNY-1 (Small Molecule) Details Weight Loss And Nicotine Addiction | IND Submission | |
MIRA-55 (Non-Opioid Analgesic) Details Inflammatory Pain | IND Submission |
